Loading...
XLONRUA
Market cap8mUSD
Dec 24, Last price  
11.00GBP
1D
0.00%
1Q
-10.20%
Jan 2017
-44.70%
Name

Rua Life Sciences PLC

Chart & Performance

D1W1MN
XLON:RUA chart
P/E
—
P/S
311.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
21.06%
Rev. gr., 5y
36.46%
Revenues
2m
+0.55%
137,0001,425,000276,0001,484,0001,259,0001,362,0001,570,0003,146,7852,497,717251,379576,855625,564490,033404,000463,000489,0001,528,0001,625,0002,179,0002,191,000
Net income
-1m
L-28.11%
-1,867,000-523,000-2,121,000-1,159,000-1,249,000-1,923,000-2,501,00035,6020-493,758-219,433-419,357-189,149-34,000-609,000-816,000-1,451,000-2,067,000-2,003,000-1,440,000
CFO
-1m
L+13.12%
-2,119,000-1,288,000-816,000-1,139,000-1,389,000-2,050,000-1,527,00050,593346,192-23,998-189,81784,704-159,620347,000-429,000-431,000-1,423,000-2,361,000-1,174,000-1,328,000
Earnings
Jul 22, 2025

Profile

RUA Life Sciences plc, together with its subsidiaries, provides polymers, services, and products to the medical device industry in Europe, the United States, and internationally. The company operates as a contract developer and manufacturer of medical devices; and licensor of Elast-Eon and ECSil implantable co-polymers that are used in cardiology and urological applications, including pacing leads, cardiac cannulae, and stent devices, as well as reaction injection molding technology for use in high-precision medical device components. It also develops bore polymer sealed grafts and soft tissue patches; and tri leaflet polymeric heart valves. The company was formerly known as AorTech International plc and changed its name to RUA Life Sciences plc in June 2020. RUA Life Sciences plc was incorporated in 1996 and is headquartered in Irvine, the United Kingdom.
URL
https://rualifesciences.com/
IPO date
Feb 12, 1997
Employees
48
Domiciled in
GB
Incorporated in
GB

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
2,191
0.55%
2,179
34.09%
1,625
6.35%
Cost of revenue
2,523
2,499
2,318
Unusual Expense (Income)
NOPBT
(332)
(320)
(693)
NOPBT Margin
Operating Taxes
(580)
(319)
(293)
Tax Rate
NOPAT
248
(1,000)
(400)
Net income
(1,440)
-28.11%
(2,003)
-3.10%
(2,067)
42.45%
Dividends
Dividend yield
Proceeds from repurchase of equity
3,974
BB yield
-131.55%
Debt
Debt current
117
110
62
Long-term debt
498
365
282
Deferred revenue
87
116
174
Other long-term liabilities
84
(91)
Net debt
(3,316)
(1,009)
(2,619)
Cash flow
Cash from operating activities
(1,328)
(1,174)
(2,361)
CAPEX
(55)
(449)
(904)
Cash from investing activities
(85)
(449)
(904)
Cash from financing activities
3,888
132
(66)
FCF
684
778
(2,744)
Balance
Cash
3,931
1,484
2,963
Long term investments
Excess cash
3,821
1,375
2,882
Stockholders' equity
(6,527)
(7,046)
(5,145)
Invested Capital
14,185
12,320
12,247
ROIC
1.87%
ROCE
EV
Common stock shares outstanding
33,566
22,185
22,185
Price
0.09
-82.52%
0.52
5.10%
0.49
-65.37%
Market cap
3,021
-73.56%
11,425
5.10%
10,871
-56.59%
EV
(295)
10,416
8,252
EBITDA
32
38
(380)
EV/EBITDA
274.11
Interest
83
16
8
Interest/NOPBT